Revenue
2019
2022
2023
2024
2025
Kalaris Therapeutics, Inc. (KLRS)
Price$3.86Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $165,000 |
| Research & development | $30.8M | $45.0M | $133.1M | $118.9M | $120.7M | $49.7M | $16.2M |
| Operating expenses | $46.2M | $51.7M | $199.9M | $171.2M | $169.8M | $71.3M | $26.9M |
| Operating income | −$46.2M | −$51.7M | −$199.9M | −$171.2M | −$169.8M | −$71.3M | −$26.7M |
| Operating margin | — | — | — | — | — | — | −16,182.42% |
| EBITDA | −$46.1M | −$66.5M | −$199.5M | −$170.5M | −$169.6M | −$71.2M | −$26.7M |
| EBITDA margin | — | — | — | — | — | — | −16,170.91% |
| Net income | −$43.4M | −$69.2M | −$190.4M | −$168.7M | −$172.0M | −$69.8M | −$23.8M |
| Net profit margin | — | — | — | — | — | — | −14,447.88% |
| Basic EPSper basic share | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | -$59.57 | -$426.42 |
| Diluted EPSper diluted share | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | -$59.57 | -$426.42 |
Owners
Reported shareholders
≈54.26%of listed shares
Samsara BioCapital, L.P. / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC / Samsara BioCapital GP, LLC / AKKARAJU SRINIVAS12.92M shares · May 20, 2026
View holders
| Holder | % owned |
|---|---|
Samsara BioCapital, L.P. / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC / Samsara BioCapital GP, LLC / AKKARAJU SRINIVAS | ≈54.26%12.92M shares |
SAMSARA BIOCAPITAL, LLC | 54.11%12.88M shares |
RTW INVESTMENTS, LP | 5.46%1.3M shares |
Sinha Vikas | ≈3.25%774.12K shares |
Brainard Diana | ≈3.04%723.36K shares |
Alyeska Investment Group, L.P. | 2.41%572.69K shares |
Ferrara Napoleone | ≈2.12%504K shares |
Siren, L.L.C. | 1.83%435.8K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.67%398.71K shares |
Ikarian Capital, LLC | 1.51%360K shares |
PATEL SAMIR CHANDRAKANT | ≈1.48%352.8K shares |
UBS Group AG | 1.10%262.13K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.63%149.35K shares |
MARSHALL WACE, LLP | 0.58%139.2K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.48%114.04K shares |
Woodline Partners LP | 0.42%100K shares |
ADAR1 Capital Management, LLC | 0.42%100K shares |
WHI TRUST Co LLC | 0.41%97.49K shares |
RAYMOND JAMES FINANCIAL INC | 0.41%97.16K shares |
CITADEL ADVISORS LLC | 0.40%95.77K shares |
Percentages use 23.8M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | Samsara BioCapital, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 244.3K | $4.83 | $1.18M | 2.22M |
| Mar 20, 2026Form 4 | Hagen Brett RChief Accounting Officer | SellCommon Stock | 1.9K | $6.72 | $12.9K | 0 |
| Dec 18, 2025Form 4 | Samsara Opportunity Fund, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 479.8K | $10.42 | $5.00M | 1.98M |
| Mar 26, 2025Form 4 | Hagen Brett RChief Accounting Officer | SellCommon Stock | 907 | $8.97 | $8.1K | 1.9K |
| Feb 21, 2025Form 4 | Sinha VikasSee Remarks | SellCommon Stock | 303 | $10.08 | $3.1K | 49.1K |